Coherus Oncology: 3 Key Takeaways for Long-Term Investors
With less than 12 months of cash on hand, the margin for error is thin, and the oncologist survey on LOQTORZI's standard-of-care status may matter as much as any cost cut.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.